ABSTRACT: Society urgently needs new, effective medicines for the treatment of tuberculosis. To kick-start the required hit-to-lead campaigns, the libraries of pharmaceutical companies have recently been evaluated for starting points. The GlaxoSmithKline (GSK) library yielded many high-quality hits and the associated data were placed in the public domain to stimulate engagement by the wider community. One such series, the Spiro compounds, are described here. The compounds were explored by a combination of traditional in-house research and open source methods. The series benefits from a particularly simple structure and a short associated synthetic chemistry route. Many members of the series displayed striking potency and low toxicity, and highly promising in vivo activity in a mouse model was confirmed with one of the analogs. Ultimately the series was discontinued due to concerns over safety, but the associated data remain public domain, empowering others to resume the series if the perceived deficiencies can be overcome.
INTRODUCTION
. Areas of variation in the synthetic chemistry towards understanding the SAR.
1) Modifications to the North.
The first region to be explored for determination of the StructureActivity Relationship (SAR) was the northern part of the molecule, with a view to replacing the thiophene group that had the potential to promote oxidative metabolism. 15 These analogs were obtained using an oxa-Pictet Spengler reaction on 1-benzyl-4-piperidinone with different aryl alcohols under mild conditions (Scheme 1). 16 Subsequent N-deprotection and reductive amination with 4-benzodioxane-6-carboxaldehyde generated the corresponding compounds that were evaluated ( Table   2 ). The thiophene isomer of 1 (i.e. 4,7-dihydro-5H-thieno [2,3-c] pyran) was found to be inactive, but the sample displayed instability under ambient conditions (visual color degradation, and appearance of new signals in the 1 H NMR spectrum) that made its assessment challenging (Compound S1, Supporting Information). Compounds 2 and 3 were instead found to exhibit superior stability and confirm the strong link between thiophene orientation and biological potency. The benzopyran analogue 4 was better tolerated than the indole analogue 6, but the addition of a methoxy group on the phenyl ring (5) in order to block potential metabolic reactions resulted in loss of potency.
Scheme 1. Synthesis of Compounds with Modifications to the Northern part
Reagents and Conditions: a) MsOH, toluene, 80°C, 3 h; b) 1-chloroethyl chloroformate, THF, -78°C, 90 min; c)
MeOH, 65°C, 1 h; d) 1,4-benzodioxan-6-carboxaldehyde (or benzofuran-2-carbaldehyde for compounds 2 and 3), NaBH(OAc)3, DCM or DCE, 40-100ºC, 1.5 -48 h. ,7'-dihydrospiro[piperidine-4,4'-thieno[3,2-c] pyran by reductive amination (Scheme 3, Table 4 ). The aldehydes employed were either commercially available or easily synthesized by adapting methods already described in the literature. 16 , 17
Table 2. Evaluation of Analogs Modified in the Northern

Scheme 3. Synthesis of Compounds with Modifications to the Southern part
Reagents and Conditions: See Experimental Section and Supporting Information. In general, placing aromatic rings in the south provided potent compounds (vs. analog lacking substituents as in 7). However, there is a very high level of sensitivity to the substitution pattern, with the unsubstituted-benzyl compound 19 and the 2-methyl analogue 22 being inactive, whilst the 3-or 4-methyl isomers (20 and 21) and the 3,4-dimethyl (23) analogue were highly potent. The fused cyclohexyl (17) analogue was found to be more potent than the parent compound 1 or the corresponding chromane analogue 16, yet the pyridyl analogue (18) was found to be inactive. Several substituents were well tolerated in the 4-position of the phenyl ring (24, 25) , as was methyl branching in the benzylic position (26, racemic) . Substitution of the phenyl ring for heterocyclic groups had varying effects, with the potency of the indole set (37-39) on the one hand, and the inactive pyrrole analogue 31 on the other. (Compound 31 was the least lipophilic analogue examined to this point; in order to evaluate the influence of polarity on metabolic stability this compound was, despite being inactive, progressed to the microsome assay but was found to be metabolically unstable.) Reasonable levels of potency were seen with a set of N-aryl pyrrole substitutions in this position (32, 33, 36), although the N-pyridyl variants (34, 35) were found to exhibit low potency. Biphenyl ether analogue with hydroxymethyl, trifluoromethoxy and bromine substituents produced very potent and fairly stable compounds (28-30).
Pharmacokinetics
In order to confirm translation of the microsomal data to an in vivo setting, the pharmacokinetic profiles of the initial hit 1 and the di-aryl analogues (27-30) that gave the best results observed in vitro were selected for in vivo PK studies following a single dose administered through oral and intravenous routes (Table 5 ). confirmed that, despite the structural changes incorporated during the optimization process, the biological target is maintained.
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In vivo Efficacy
The efficacy of compound 29, showing promising pharmacokinetic profile and high in vitro potency, was studied in an acute TB murine infection model. The data obtained are shown in Figure 2 .
Compound 29 proved to be very efficacious showing a -cidal response, 4.2 log CFU reduction compared to the untreated control, similar to isoniazid. The good result obtained in a short assay in which the compound is administered only for 8 days is evidence for a fast-killing profile. ED99
(Efficacious Dose that gives 2 log colony-forming units (CFU) reduction compared to the untreated control) was 11.6 mg/kg. This encouraging value, although higher than that of isoniazid, is in the range of most existing antitubercular dugs. A maximum recommended dose of 50 mg/kg was used since tolerability issues had been observed at higher doses. The exciting results that confirmed the potential of this chemical series to efficiently kill Mtb in vivo prompted us to continue our medicinal chemistry efforts towards optimization of compound 29. 
Decreasing Lipophilicity
Despite its remarkable efficacy, a number of factors precluded further progression of compound 29 (see Tables 6 and 7 ). The Cell Health (CH) assay is a triple-readout phenotypic assay measuring changes in cell structure as a preliminary consequence of cytotoxic injury. The assay uses automated imaging to measure IC50 values for the effect of compounds on human liver-derived HepG2 cells (48 h incubation) as a surrogate of hepatotoxicity. For high doses (>100 mg/day), an IC50 value lower than 80 µM in any of the readouts of the assay is considered an indication of high hepatotoxicity risk (see Table 6 for data of compound 29). Both high doses and long treatments, considered as an additional risk factor, are common to antitubercular drugs. Inhibition of the human ether-a-go-go-related gene (hERG) channel was also a concern for potential cardiotoxicity (see below and Table 7 for discussion). Additionally, the compound presented a poor solubility and high lipophilicity. We envisioned that a decrease of the latter would be a reasonable strategy to improve the general ADMET profile of compound 29. At this stage, we used the property forecast index (PFI), a more relevant measure of the lipophilicity of the compounds, to guide the design of new analogs. PFI is the sum of 
Isoniazid
Compound 29 the Chrom LogD7.4 and the number of aromatic rings and values lower than 7 predict promising compounds in terms of solubility, permeation, cytochrome P450s, intrinsic clearance, and hERG binding and promiscuity. 18 In an effort to reduce lipophilicity (compound 29 has a PFI value of ca. 12), several compounds lacking the thiophene ring were proposed that afforded improved predicted PFI values (Table 6) ; such changes had not previously been addressed in modifying the northern part of the molecule (Table 2) .
Accordingly, these compounds ( clearance rates, but with generally lower potency than compound 50.
As mentioned above, the cardiovascular risk associated to hERG inhibition was also a concern that needed to be monitored so in vitro hERG data were generated for a selection of compounds (Table 7) . The in silico prediction from the structures pointed to potential hERG channel inhibition in vitro in mammals for compounds 29, 30 and 42. This alert describes a structure-based pharmacophore developed primarily from compounds that have been reported to be strong inhibitors of the hERG potassium channel. 18 An ion channel inhibition in vitro assay, carried out using automated planar chip electrophysiology platforms IonWorks (IW) and PatchExpress (PXP), confirmed the alert. Although the less lipophilic compound 50 did not show an in silico alert, the experimental hERG inhibition was decreased by less than one order of magnitude. We decided to assess if the cardiovascular liability of the series was also observed in ex vivo studies (perfused rabbit ventricular wedge assay, RVW) with compound 50 (Table 8) . 
CONCLUSIONS
Through exploration of a class of small molecule spirocyclic compounds, made easier by the ease with which the compounds can be accessed synthetically, we have identified highly potent antitubercular compounds. Several compounds examined possessed good pharmacokinetic properties.
Most importantly, a representative member of the series displayed remarkable potency in an in vivo model of the disease. These features would normally mark the series out as highly promising for further investigation, but a significant risk of hERG inhibition and a lower-than-desired in vivo tolerability have combined to lead us to park the series. There may be ways to engineer around these series liabilities and members of the broader drug discovery community may discover such solutions.
To encourage collaboration with an open source research mechanism, the data and related materials for the series are posted on a community resource created for this purpose, 20 adopting principles that have driven open source research mechanisms in other disease areas. 17c Any scientist interested in furthering this series, or adopting an open approach to other series, is encouraged to do so using this free online infrastructure.
EXPERIMENTAL SECTION
We can confirm that all animal studies were ethically reviewed and carried out in accordance with
European Directive 2010/63/EU and the GSK Policy on the Care, Welfare and Treatment of Animals.
Compound synthesis. All commercially available reagents and solvents were used without further purification. High performance liquid chromatography (HPLC) was used to determine the purity of the compounds synthesized. The data confirmed that the target compounds generally had ≥95% of purity with the exception of compounds 14 (90%), 18 (91%), 23 (90%), 36 (90%) and 47 (85%).
When reactions were performed under microwave conditions, a Biotage Initiator was used. The yields refer to the purified products, and they were not optimized. Reactions were monitored by TLC on silica gel with detection by UV light (254 nm) and/or stained with the relevant reagent. TLC analysis was performed using Merck Silica Gel 60 F254 precoated aluminium plates (0.2 mm) or Polygram precoated silica gel TLC sheets SIL G/UV254. When necessary, crude reaction products were purified by using flash chromatography, ion exchange purifications and/or preparative HPLC. Flash purifications were usually performed on a Biotage ISOLERA One flash system equipped with an internal variable dual wavelength diode array detector (200−400 nm). SNAP cartridges (10−100 g, flow rate of 10−100 mL/ min) were used. Dry sample loading was done by selfpacking samplet cartridges using silica or Celite 545. Gradients used varied for each purification. However, typical gradients used for normal phase were gradients of 0−100% ethyl acetate in cyclohexane or 0−15% methanol in CH2Cl2. For Ion-exhange purifications, SOLUTE® SCX-2 Ion-exchange columns (1-50 g) were used with elutions of MeOH followed by 7 N NH3 in MeOH. Purification using prep-HPLC was accomplished using a Gilson HPLC system with a Gemini 5 μm C18 column (150 mm × 21.2 mm i.d.). Typically, the mobile phase used for HPLC was a linear gradient of water (A) and acetonitrile (B). The water and acetonitrile were mixed with 0.1% TFA or 0.1% HCOOH. The flow rate was maintained at 0.8−1.2 mL/min for analytic HPLC and 20 mL/min for prep-HPLC, and the eluent was monitored with UV detector at 220 nm. Characterization of all final compounds was performed using 1 H NMR spectroscopy and mass spectrometry. 
General Procedure A. Reductive amination
A solution of secondary amine (1 equiv) and the appropriate aldehyde (1-1.1 equiv) in CH2Cl2 or DCE (molarity 0.05-0.14 M) was stirred at rt for 1-4 h. Sodium triacetoxyborohydride or solidsupported Amberlite ® IRA-900 cyanoborohydride (1-6 equiv) was added and the reaction was stirred at room temperature or 40-100 ºC for 1.5-48 h. After allowing to cool, the reaction was quenched by addition of saturated NaHCO3 solution and extracted with CH2Cl2, the organic layer was dried (Na2SO4), filtered and concentrated to afford a crude mixture that was purified by column chromatography and/or preparative HPLC to give the corresponding tertiary amine.
General Procedure B. Reductive amination
A solution of secondary amine (1 equiv), the appropriate aldehyde (1-1.1 equiv), Biotage® MPCyanoborohydride (1.7 equiv) or solid-supported Amberlite ® IRA-900 cyanoborohydride (1-1.7 equiv) and acetic acid (4 equiv) in CH2Cl2 (molarity 0.06-0.16 M) was subjected to MW irradiation for 40-180 min at 100 ºC. The reaction was filtered, quenched by addition of saturated NaHCO3 solution and extracted with CH2Cl2. The organic layer was dried (Na2SO4), filtered and concentrated to afford a crude mixture that was purified by column chromatography or preparative HPLC to give the corresponding tertiary amine.
1-(4-Phenoxybenzyl)-6',7'-dihydrospiro[piperidine-4,4'-thieno[3,2-c]pyran] (27)
The title compound was prepared using General Procedure A. White solid, yield 80% (600 mg, 1.532 mmol 
4-Bromo-N-(4-((6',7'-dihydrospiro[piperidine-4,4'-thieno[3,2-c]pyran]-1-yl)methyl)phenyl)aniline, hydrochloride (30)
The compound as a free amine was obtained using the general procedure B with 30b (see Supporting Information) as colorless oil. The compound as a free amine (480 mg, 1.02 mmol) was dissolved in CH2Cl2 (3 mL) and treated with 2 M HCl in Et2O (0.51 mL, 1.02 mmol). 
9-(4-(4-(Trifluoromethoxy)phenoxy)benzyl)-1-oxa-9-azaspiro[5.5]undecane, hydrochloride (42)
The compound as a free amine (91 mg, 0.218 mmol) was obtained using General Procedure A and 58 as a pale yellow oil. The compound as a free amine was dissolved in CH2Cl2 (5 mL) and 1 M HCl in Et2O (0.218 mL, 0.218 mmol), the solvent was evaporated to obtain the hydrochloride salt of the compound. White solid, yield 47% (100 mg, 0.218 mmol). 
tert-Butyl 4-allyl-4-hydroxypiperidine-1-carboxylate (55)
Allylmagnesium bromide in Et2O (1 M, 29.1 mL, 29.1 mmol) was slowly added to a solution of tertbutyl 4-oxopiperidine-1-carboxylate (5.0 g, 25.1 mmol) in Et2O (80 mL) at 0ºC. The reaction mixture was allowed to warm to rt overnight. The reaction was quenched by addition of saturated NH4Cl solution and the organic layer was separated, dried (Na2SO4), filtered and evaporated to obtain a yellow oil (4.9 g). A fraction of crude (2 g) was purified by flash chromatography to obtain the title compound. Pale yellow oil, yield 45% (1.1 g, 4.56 mmol). 
tert-Butyl 4-allyl-4-(allyloxy)piperidine-1-carboxylate (56)
Allylbromide (1.082 mL, 12.43 mmol) was added to a solution of 55 (1.0 g, 4.1 mmol) in DMF (20 mL) at 0ºC. After 5 min, NaH (0.167 g, 6.63 mmol) was added. The reaction mixture was allowed to warm to rt and stirred for 48 h. The reaction mixture was portioned between water and TBME. The organic layer was separated, washed with water (3  20 mL), dried (MgSO4) and concentrated. The crude product was purified by flash chromatography to afford the title compound. Pale yellow oil, yield 67% (780 mg, 2.77 mmol). 1 H NMR (400 MHz, CDCl3) δ ppm: 5. 98-5.88 (m, 1H), 5.86-5.75 (m, 1H), 5.34-5.28 (m, 1H), 5.17-5.05 (m, 3H), 3.97-3.89 (m, 2H), 3.79-3.77 (m, 2H), 3.11-3.07 (m, 2H), 2.28 (d, 2H, J=6.9) 
1-Oxa-9-azaspiro[5.5]undecane, hydrochloride (58)
Pd/C (281 mg, 0.264 mmol) was added to a solution of 57 (670 mg, 2.64 mmol) in MeOH (15 mL).
The reaction was hydrogenated at 2.5 bar for 2 h. The reaction was filtered over Celite® and concentrated to afford the free amine. Off-white solid, yield 97% (658 mg, 2.58 mmol).
H NMR (400
MHz, CDCl3) δ ppm : 3.73-3.70 (m, 2H), 3.66-3.63 (m, 2H), 3.50-3.49 (m, 2H), 3.15-3.12 (m, 2H) Procedure for PK Studies. For pharmacokinetic studies, C57BL/6 female mice (18-20 g ) were used and compound concentrations were determined using peripheral whole blood. Murine Model of Acute TB Infection. Specific pathogen-free, 8-10 week-old female C57BL/6 mice were purchased from Harlan Laboratories and were allowed to acclimate for one week. The experimental design for the acute assay has been previously described. 22 In brief, mice were intratracheally infected with 100,000 CFU/mouse of M. tuberculosis H37Rv. Compounds were administered for 8 consecutive days starting one day after infection. One mouse was administered per product and dose. Lungs were harvested 24 hours after the last administration and all lung lobes were aseptically removed, homogenized and frozen. Homogenates were plated onto 10% OADC-7H11 medium supplemented with activated charcoal (0.4%) and incubated for 18 days at 37 °C. The viable CFU were converted to Log10, which were then fitted to a sigmoidal dose/response curve (GraphPad Prism Software).
Cell Health. The Cell Health (CH) assay is a 3-parameter automated imaging cell-based assay to measure the cytotoxic effect of compounds in human liver derived HepG2 cells. 23, 24 In brief, the key parameters measured in this assay using fluorescent staining are nuclear size, mitochondrial membrane potential and plasma membrane permeability. HepG2 cells (Biocat #97134) were incubated with the test compounds in 384-well plates, and after 48 h the staining cocktail was added:
Hoechst 33342 is used to stain nuclei and quantify changes in nuclear morphology; TMRM is a cationic dye that accumulates in healthy mitochondria that maintain a mitochondrial membrane potential. This dye leaks out of the mitochondria when the mitochondrial membrane potential is dissipated; TOTO-3 iodide labels nuclei of permeabilized cells and is used to measure plasma membrane permeability.
Following 45 min incubation, the plate was sealed for reading on INCell 2000 (GE Healthcare). Each parameter produced a % of cells which were 'LIVE' or 'DEAD'. Analysis of data showed the IC50, the compound concentration that produced 50% of inhibition of growth of cells.
Hydrophobicity Assay (ChromlogD). 10 mL of 10 mM DMSO stock solutions were diluted to 750 mL with octanol saturated phosphate buffer pH 7.4 and 160 mL buffer saturated octanol in a 96-well deep well block. Blocks were sealed and inverted for 3 sets of 50 inversions, then centrifuged at 300 g for 20 min. Both phases were then quantified using generic gradient UV-HPLC.
Chemiluminescent Nitrogen Detection (CLND) Solubility. 5 mL of 10 mM DMSO stock solution was diluted to 100 mL with phosphate-buffered saline, pH 7.4, equilibrated for 1 h at room temperature, and filtered through Millipore Multiscreen HTS-PCF filter plates (MSSL BPC). or Qpatch 48HTX (Sophion Bioscience, Copenhagen) was measured. Data for each well for each compound was transformed to a fraction of the baseline current and a pIC50 was obtained.
Subsequently ex vivo assay was performed to confirm the risk flagged from in vitro ion channel assays. Surgical preparation of the rabbit left ventricular wedge has been described in detail previously. 19 Briefly, female New Zealand white rabbit was anaesthetized and the heart removed and immediately cannulated and perfused with cold cardioplegic solution (24 mM potassium (K+), buffered with 95% O2/5% CO2). A transmural wedge was dissected from the left ventricle. The preparation was placed in a tissue bath and arterially perfused with Tyrode's solution (4 mM K+,
